Regenxbio Inc Market Cap ($487.18 Million)
Market Cap & Net Worth: Regenxbio Inc (RGNX)
Regenxbio Inc market cap. Regenxbio Inc (NASDAQ:RGNX) has a market capitalization of $487.18 Million ($487.18 Million) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12076 globally and #3031 in its home market, demonstrating a 1.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regenxbio Inc's stock price $7.38 by its total outstanding shares 66013192 (66.01 Million). Also see Regenxbio Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Regenxbio Inc Market Cap History (2015–2026)
Regenxbio Inc market cap history from 2015 to 2026. Data shows change from $1.10 Billion to $487.18 Million (-7.32% CAGR). Check Regenxbio Inc share price for real-time trading data and today's change.
Index Memberships
Regenxbio Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.02% | #327 of 976 |
|
NASDAQ Composite
IXIC
|
$38.55 Trillion | 0.00% | #1206 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.82 Trillion | 0.03% | #184 of 263 |
Weight: Regenxbio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Regenxbio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regenxbio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RGNX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.58x
Regenxbio Inc's market cap is 5.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.22 Billion | $4.59 Million | -$62.97 Million | 266.84x | N/A |
| 2017 | $2.19 Billion | $10.39 Million | -$73.17 Million | 211.19x | N/A |
| 2018 | $2.77 Billion | $218.50 Million | $99.94 Million | 12.67x | 27.71x |
| 2019 | $2.70 Billion | $35.23 Million | -$94.73 Million | 76.76x | N/A |
| 2020 | $2.99 Billion | $154.57 Million | -$111.25 Million | 19.37x | N/A |
| 2021 | $2.16 Billion | $470.35 Million | $127.84 Million | 4.59x | 16.89x |
| 2022 | $1.50 Billion | $112.72 Million | -$280.32 Million | 13.28x | N/A |
| 2023 | $1.18 Billion | $90.24 Million | -$263.49 Million | 13.13x | N/A |
| 2024 | $510.28 Million | $83.33 Million | -$227.10 Million | 6.12x | N/A |
| 2025 | $950.59 Million | $170.44 Million | -$193.88 Million | 5.58x | N/A |
Competitor Companies of RGNX by Market Capitalization
Companies near Regenxbio Inc in the global market cap rankings as of November 7, 2026. Also see how large is Regenxbio Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to Regenxbio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Regenxbio Inc (2015–2026)
Market capitalization of Regenxbio Inc from 2015 to today. Between 2015 and today, Regenxbio Inc's market cap moved from $1.10 Billion to $ 487.18 Million, with a yearly change of -7.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $487.18 Million | -48.75% |
| 2025 | $950.59 Million | +86.29% |
| 2024 | $510.28 Million | -56.94% |
| 2023 | $1.18 Billion | -20.86% |
| 2022 | $1.50 Billion | -30.64% |
| 2021 | $2.16 Billion | -27.91% |
| 2020 | $2.99 Billion | +10.72% |
| 2019 | $2.70 Billion | -2.34% |
| 2018 | $2.77 Billion | +26.17% |
| 2017 | $2.19 Billion | +79.25% |
| 2016 | $1.22 Billion | +11.75% |
| 2015 | $1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Regenxbio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $487.18 Million USD |
| MoneyControl | $487.18 Million USD |
| MarketWatch | $487.18 Million USD |
| marketcap.company | $487.18 Million USD |
| Reuters | $487.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more